Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Type:
Application
Filed:
December 16, 2011
Publication date:
May 31, 2012
Applicant:
Medlmmune, LLC
Inventors:
Chin-Fen Yang, George Kemble, Chongguang Liu
Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.
Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognoses to patients having IFN?-induced disorders.
Type:
Application
Filed:
June 19, 2009
Publication date:
November 24, 2011
Applicant:
Medlmmune, LLC
Inventors:
Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener, Barbara White
Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
Type:
Application
Filed:
December 17, 2010
Publication date:
October 6, 2011
Applicant:
Medlmmune, LLC
Inventors:
Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
Abstract: This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration.
Type:
Application
Filed:
April 1, 2011
Publication date:
October 6, 2011
Applicants:
Medlmmune, LLC, The Regents of the University of Colorado
Inventors:
Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
Abstract: Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.
Abstract: The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient.
Type:
Application
Filed:
June 25, 2008
Publication date:
January 13, 2011
Applicant:
Medlmmune, LLC
Inventors:
Subramaniam Krishnan, JoAnn Suzich, Peter Kiener, Genevieve Losonsky, Herren Wu, William Dall'Acqua, Bettina Richter
Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.
Type:
Application
Filed:
September 1, 2010
Publication date:
December 30, 2010
Applicants:
Medlmmune, LLC, The Regents of the University of Colorado, a body corporation
Inventors:
Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
Abstract: The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention.
Type:
Application
Filed:
January 19, 2010
Publication date:
November 4, 2010
Applicant:
Medlmmune, LLC
Inventors:
Ziping Wei, Guillermo Tous, Mark Schenerman, Christian B. Allan
Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.
Type:
Application
Filed:
September 18, 2009
Publication date:
August 5, 2010
Applicant:
Medlmmune LLC
Inventors:
David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
Abstract: The invention relates to improved strains of mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention further relates to methods for propagating mammalian MPV in the absence of trypsin. The methods and compositions of the invention can be used for the preparation of vaccines against, e.g., MPV infections.
Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.
Abstract: The present invention provides prophylactic an therapeutic protocols designed to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managing, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits.
Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Type:
Application
Filed:
October 31, 2008
Publication date:
July 9, 2009
Applicant:
Medlmmune, LLC
Inventors:
Chin-Fen Yang, George Kemble, Chongguang Liu
Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.
Type:
Application
Filed:
May 7, 2008
Publication date:
November 13, 2008
Applicant:
Medlmmune, LLC
Inventors:
Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen